Frequently Asked
What WADA Says.
Direct, source-cited answers to the ten questions search demand actually concentrates around. Editorial commentary only — not legal advice.
Is GHK-Cu legal?
It depends on the form and the use. As a cosmetic ingredient — copper tripeptide-1 on the INCI list — GHK-Cu is permitted in topical products in the US, the EU, and the UK [1][2]. As a drug, it has no FDA approval for any therapeutic indication. As a research chemical, it is sold with a non-human-use label and must be kept within that regulatory boundary. Injectable GHK-Cu has historically faced FDA scrutiny under Section 503A compounding rules, and its bulks-list status has moved more than once — verify the live FDA position directly before relying on any specific status [3]. It is not a scheduled controlled substance under the US Controlled Substances Act or the UN single conventions.
Is GHK-Cu FDA-approved?
No GHK-Cu drug has received FDA approval for any indication. No New Drug Application has cleared. Per the FDA, structure/function or disease-treatment claims about a topical or injectable GHK-Cu product can transform that product into an unapproved new drug under the Federal Food, Drug, and Cosmetic Act [5]. As a cosmetic ingredient, copper tripeptide-1 is not pre-approved by the FDA — under MoCRA and the FD&C Act, manufacturers are responsible for substantiating the safety of cosmetic ingredients themselves, and the Cosmetic Ingredient Review Expert Panel's 2018 review is the standing US safety reference for typical use concentrations [1][5]. Always verify the current status at fda.gov.
Is injectable GHK-Cu legal in the United States?
Injectable GHK-Cu sold as a research chemical for non-human laboratory use is lawful under the same framework that governs other research-grade peptides — with a strict non-human-use designation that is a regulatory condition, not optional branding. Compounded injectable GHK-Cu prepared for human administration sits in a more contested space. Section 503A of the FD&C Act governs traditional compounding pharmacies, and a bulk substance must be on the FDA's bulks list (or be the subject of an applicable USP monograph, or be a component of an approved drug) to be eligible for compounding. Industry summaries indicate injectable GHK-Cu has been placed in Category 2 (significant safety risk) on the interim 503A bulks list, citing immunogenicity and impurity concerns, and a 2026 industry report indicated removal pending further Pharmacy Compounding Advisory Committee review [3]. The live status moves; check the FDA bulks list page directly.
Is GHK-Cu safe to use in cosmetics and skincare?
The Cosmetic Ingredient Review Expert Panel reviewed copper tripeptide-1 in 2018 and concluded that it is safe as used in cosmetics at typical concentrations, commonly cited as 0.05 to 1 percent w/w [1]. The EU permits it as a cosmetic ingredient under Regulation (EC) No. 1223/2009 with the responsibilities of safety substantiation, Cosmetic Product Safety Report production, and Responsible Person designation falling on the manufacturer [2]. The UK retains an essentially identical framework post-Brexit. Note that 'safe as a cosmetic ingredient' is not the same as 'approved as a drug' — a topical product can be lawful as a cosmetic while becoming an unapproved drug the moment it makes therapeutic claims.
Is GHK-Cu banned by WADA for athletes?
GHK-Cu is not explicitly named on the current World Anti-Doping Agency Prohibited List [6]. However, WADA uses broad 'similar substances' language across several categories — including peptide hormones, growth factors, and related substances — and an athlete subject to anti-doping rules cannot rely on the absence of an explicit name. Each year's Prohibited List can change; the in-force edition at the time of competition is what matters. Athletes should consult the most recent WADA Prohibited List, their international federation's rules, and their national anti-doping authority before any use. This site does not advise on competition status.
Can a compounding pharmacy legally prepare GHK-Cu?
It depends on the route and the live FDA bulks list. Compounding pharmacies operating under Section 503A may compound from bulk substances that are on the FDA's 503A interim bulks list (or otherwise meet the statutory criteria). Industry summaries indicate topical GHK-Cu has been treated as Category 1 (the FDA does not intend to take enforcement action against its use in compounding), while injectable GHK-Cu has at points been placed in Category 2 (significant safety risk) and then, per a 2026 industry summary, removed pending further PCAC review [3]. Outsourcing facilities under Section 503B operate under a separate bulks list. The status of any specific bulk substance changes; compounders and prescribers must confirm directly with the FDA's primary bulks list page and Federal Register notices before reliance [30].
What is the difference between cosmetic-grade and research-grade GHK-Cu?
Cosmetic-grade copper tripeptide-1 is produced and tested to specifications that allow its incorporation into finished cosmetic products lawfully placed on the US, EU, or UK market — meaning purity, microbiological standards, and stability are validated for topical use, and the manufacturer can substantiate safety to the CIR or CosIng standards [1][2][27]. Research-grade GHK-Cu is sold for laboratory use only, with a non-human-use label that is a regulatory designation, not a quality certification. Purity, copper-loading ratio, and endotoxin status are not standardized across research-chemical vendors, and the lack of validated standards is one of the substantive concerns underlying FDA caution on injectable use [29]. The two grades may be the same molecule on paper; the quality systems and regulatory standing behind them are not equivalent.
Is GHK-Cu legal in the European Union?
Yes, as a cosmetic ingredient. GHK-Cu is catalogued in the EU CosIng database under the INCI name 'Copper Tripeptide-1' at reference 55687 [2]. Cosmetics containing it are regulated under Regulation (EC) No. 1223/2009; each finished product requires a Cosmetic Product Safety Report (CPSR) and a designated Responsible Person established in the EU before being placed on the market. The 2024 IJDRA compliance review surveys EU rules alongside US MoCRA and Asia-Pacific frameworks and is a useful map of the cosmetic regulatory perimeter [27]. As with the US, lawful cosmetic status does not constitute drug approval, and the same claim-boundary distinction applies.
Can I sell GHK-Cu skincare products without FDA approval?
Cosmetic products are not pre-approved by the FDA under either the FD&C Act or MoCRA. A skincare product containing copper tripeptide-1 can be marketed in the US without FDA pre-approval, but the manufacturer is responsible for substantiating the safety of ingredients and finished product, complying with MoCRA's facility registration and product listing requirements, and following labeling rules [5]. The catch is the claim-boundary: cosmetic claims (appearance, feel, look) are permitted; structure/function or disease-treatment claims convert the product into an unapproved drug requiring an approved NDA or appropriate OTC monograph compliance [27]. This site does not advise on commercial product launches — consult an FDA-experienced regulatory attorney.
What therapeutic claims about GHK-Cu would trigger drug regulation?
The FDA's framework distinguishes cosmetic claims (intended to affect appearance) from drug claims (intended to affect the structure or function of the body, or to treat disease). On a topical GHK-Cu product, claims such as 'improves the appearance of fine lines,' 'supports skin firmness and texture,' or 'appears to even skin tone' generally fall within the cosmetic category. Claims such as 'heals wounds,' 'reverses aging,' 'treats hair loss,' 'regenerates skin,' or 'reduces inflammation' have historically been treated by the FDA as drug claims, converting the product into an unapproved new drug under the FD&C Act [5][27]. The same molecule, the same concentration, the same packaging — but the marketing copy can flip the legal category. This is a long-established framework, but the specific wording the FDA accepts as cosmetic versus drug evolves; the 2024 IJDRA review and FDA's own cosmetic labeling guidance are the starting points [5][27].
Does GHK-Cu work?
For topical cosmetic and post-procedure healing endpoints, the published clinical evidence is real and replicated: improved skin density, elasticity, and fine-line scores in placebo-controlled facial trials [20], faster re-epithelialization and reduced erythema after CO2 laser resurfacing [21], and ultrasound-measured collagen density gains in a small open-label topical study [22]. For hair-loss endpoints there is ex-vivo dermal-papilla cell work [23][24] but limited controlled human trial data specifically on GHK-Cu monotherapy. For injectable therapeutic use in humans, there is essentially no controlled clinical trial dataset, and the substantial preclinical and transcriptomic data should not be confused with proven human therapeutic efficacy. 'Works for what, and at what dose, by what route' is the question that matters.